These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 24099116

  • 1. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO, Calderon MA, Durham SR.
    Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, Bahceciler NN, Barlan IB.
    J Investig Allergol Clin Immunol; 2015 Nov; 25(5):334-42. PubMed ID: 26727762
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB.
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Papadopoulos NG, Sokolowska M, Angier E, Fernandez-Rivas M, Pajno G, Pfaar O, Roberts GC, Ryan D, Sturm GJ, van Ree R, Varga EM, van Wijk RG, Yepes-Nuñez JJ, Jutel M.
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M, Bagnasco D, Passa-Lacqua G, Puggioni F, Varricchi G, Canonica GW.
    Curr Pharm Biotechnol; 2017 May; 18(5):378-383. PubMed ID: 28413977
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.
    JAMA; 2016 Apr 26; 315(16):1715-25. PubMed ID: 27115376
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
    Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, Nguyen H, Montagut A, Zeldin RK.
    J Allergy Clin Immunol; 2014 Jun 26; 133(6):1608-14.e6. PubMed ID: 24388010
    [Abstract] [Full Text] [Related]

  • 15. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB.
    Int Arch Allergy Immunol; 2012 Jun 26; 157(3):288-98. PubMed ID: 22041501
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH, Xu C, Liu L, Chai RN.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun 06; 56(6):774-783. PubMed ID: 35785859
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.
    Jordakieva G, Kundi M, Lemell P, Zieglmayer R, Zieglmayer P, Godnic-Cvar J, Jensen-Jarolim E.
    Sci Rep; 2017 May 31; 7(1):2555. PubMed ID: 28566688
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.
    J Allergy Clin Immunol; 2016 Dec 31; 138(6):1631-1638. PubMed ID: 27521719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.